Member Info for Tyke68

Just read it.

Well we were told a comprehensive update was coming and I would call that comprehensive. Thank you MS/TB and team. I would call it very honest about they have been trying to do too much, we have stated that on numerous occasions.

Only revenue mentioned, from first glance, was Kirkstall and now we know more that does now sound a wise investment as per what TB was alluding to.

GAM, resulted submitted and maybe still has value if people want our data let’s wait and see.

The last paragraph from TB acknowledges how we all feel.

Me personally I am happy with that and hope what we did a few weeks back contributed to that comprehensive update being released. Thank you everybody for that.

Now let’s see how the sp reacts. Good news normally equals a drop, let’s hope we get surprised.

Thanks

Mornington

Not showing up as a RNS out anywhere I can see as of yet

Thanks

There must be a reason they want them. I can’t see them buying them just in case. Somebody just sold over 450k.

Watch this space.

Thanks

Drax

You may want to give it a few more weeks to see if we get any positive news and then it should get back above 1p.

I would say it can’t get any lower but we know that isn’t true unfortunately.

Do what’s best for you but if we have suffered major losses then so has the board including the Schmainda’s and after all their work they will want to see a profit. That’s why I can’t see them defaulting as Kane mentioned because that would wipe out the Schmainda’s holding as well

Thanks

Thanks

CL

My self imposed deadline is the end of April for the following:

Phase 1 results

Comprehensive update on all products including GaM

Annual results and hopefully an indication of future revenue

I have still got faith but it was severely dented with the last RNS. The board need to regain our trust. Plus they need to remember we own over 5% of the company.

Unfortunately we need a bit more patience but I can understand everybody’s frustration.

If anybody wants to contact the company and ask about a shareholder update please feel free. I think Max and I have done our asking for a while.

Thanks

Max

Similar to me then that’s why I asked

Thanks

Kane

No offence taken

I am in a similar position, I think the highest price I paid was 10p a share so down 95% on that investment. Let’s just see what happens in next few months.

In theory the phase 1 results should be this week if CC stuck to the fda guidelines (results 12 months from primary completion). Last week when I said GaM currently had zero value regarding the PRV vouchers people totally disagreed. Then there was no RNS issued as expected so they have gone quiet. We wait and hope and see if we do get a comprehensive update any time soon. Max, have you spoke to MS recently?

Thanks

Kane

You use the term us so I assume you are still invested even though you think we will default soon. If you are that sure why not invest in something else unless you still believe IBAI can turn this around. Let’s see what happens hopefully we get a positive surprise soon.

Thanks

I forgot we had fast track designation. I hope TB remembers it when touting GaM to any prospective buyers.

Thanks

For those interested in how difficult the clinical trial is to write up. Here is the link, to another investigating GBM, https://www.neurology.org/doi/10.1212/NXI.0000000000200530

Thanks

The last sentence!

“INTRODUCTION We previously reported that gallium maltolate (GaM) monotherapy has a profound cytotoxic effect on glioblastoma (GBM) cells in vitro and in vivo. Recent in vitro data suggests that GaM may act as a radiosensitizer, which could dramatically change how brain tumors are treated. These findings prompted further investigation into the potential neurotoxic effects of GaM alone and in combination with radiation therapy (RT). METHODS Athymic rats were inoculated intracranially with treatment-resistant U87MG GBM cells. After tumor confirmation on MRI, animals received oral GaM 50mg/kg/day or vehicle. A pilot cohort received RT (21 Gy) 28 days later. MRI was performed on a 9.4T Bruker preclinical scanner using our custom acquisition protocol that included pre- and post-contrast anatomical T1 and T2 sequences, and DSC perfusion imaging. Longitudinal MR spectroscopy was collected from 2mm3 voxels placed in enhancing and non-enhancing areas. MRI studies were repeated every 10-14 days. Data was processed using Imaging Biometrics and Bruker Paravision analysis software, as well as custom-made MATLAB scripts. RESULTS Brain microvascular cells were unaffected by GaM therapy in vitro and in vivo. Advanced MRI biomarkers, such as fractional tumor burden maps, highlighted the cytotoxic effect of GaM on xenograft tumors but not on surrounding brain parenchyma. The addition of a subclinical RT dose did not alter these findings. Absence of necrosis-marking vinyl and lactate peaks on MR spectra, as well as histology, confirmed the safety profile of combination GaM+RT. Additionally, MR spectra of non-tumor brain following acute (14 days of GaM) were comparable to those of chronic (47 days of GaM) treatment, indicating no metabolic changes. Finally, absence of sensorimotor deficits provided further evidence of GaM’s safety. These results are being validated currently in a larger cohort of animals. CONCLUSION GaM therapy does not cause overt neurotoxicity and is associated with excellent quality of life.”

From https://www.researchgate.net/publication/397501606_EXTH-134_The_oral_iron_mimetic_gallium_maltolate_is_neurologically_safe_in_a_rat_xenograft_model_of_glioblastoma_multimodal_assessment

But what will the phase 1 show? The possibility of vouchers may interest some if they could be done by 2029 but “excellent quality of life” may create more of a buzz and maybe even a bidding war when the phase 1 results are published. Or then again it might not.

Thanks

Well another week of false hopes. We all do this research looking for positives but until we hear from the company we are just all wishful thinking and waiting for the RNS red dot to appear. Nothing we can do at the moment. I hope everyone tries and enjoy the weekend and let’s see what next week brings. In theory that will be 12 months and the phase 1 report should be submitted.

Thanks

Thanks

Thanks Max

I notice AM was linked so that’s positive

AM always seemed more interested in the imaging side

Thanks

Mallettp

We are waiting for a RNS to inform us of all updates and I would assume this would be mentioned in this if the board thought it relevant. If GaM is totally sidelined for ever then the PRD designation and any vouchers would be irrelevant unless we sold the rights. We have had no indication they are going to sell the rights as of yet, hopefully that may change

Thanks

Is the bit about funding good for IBAI with its ODD or better for MCW to go alone?

“The Give Kids a Chance Act: In addition to the reauthorization for the PRV Program, the Give Kids a Chance Act provides new pediatric cancer funding and FDA authorities, clarifies how the FDA applies the exclusivity provisions of the Orphan Drug Act, and gives the FDA the ability to provide more information in the development of generic drugs. “

Thanks

Mallettp

I hope you are right but so far we have no indication of anybody willing to pay anything for our data and designations. We are all waiting for CC to submit the results for peer review and MS’s latest update.

Currently we are worth just over £1m and nobody is willing to take a chance on us.

Thanks

Linandy I know that but currently nobody appears willing to pay for it and we can’t afford the time or money to use it so it is £0 until we get a buyer or the market decides it should be priced into the sp which it currently isn’t.

Thanks

At the moment the value of all the designations and the data is £0. Until somebody decides they want to purchase or licence it it will continue to be £0.

Thanks

The reality is we don’t have a voucher, just designation. FDA needs to approve GaM first which is a long way off especially as we seem to have stopped applying for for breakthrough drug designation.

We don’t know how much somebody would pay for the GaM data in its present state, the new paediatric trial we don’t sponsor but appears to use our data.

Still good news but not as good as we hoped before the last RNS

Thanks

Max

I think we still hold the rights to all the designations (from the RNS) and the data (from TB)

So like cautious I think this makes the sale of the rights to GaM even more worthwhile to prospective buyers. Didn’t the previous designations also mention could claim against tax?

If the results are as good as we hope, the EAP data backs it up, plus use in other possible cancer treatments via (Vivan) then their must be a company out there willing to take a chance on it. The question is how much would TB sell for? We all know he loves a special dividend.

Phase 1 results

Comprehensive update

Results and what sales are we now generating for the IB products?

The wait is excruciating but hopefully it will finally be worthwhile.

Thanks